Prosecution Insights
Last updated: April 19, 2026
Application No. 18/995,166

PROCESSES FOR PRODUCING NITRILES AND PHOSPHORUS-CONTAINING CATALYSTS FOR USE IN SUCH PROCESSES

Non-Final OA §103§112
Filed
Jan 16, 2025
Examiner
RODRIGUEZ-GARCIA, VALERIE
Art Unit
1621
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Inv Nylon Chemicals Americas LLC
OA Round
1 (Non-Final)
69%
Grant Probability
Favorable
1-2
OA Rounds
2y 6m
To Grant
99%
With Interview

Examiner Intelligence

Grants 69% — above average
69%
Career Allow Rate
558 granted / 811 resolved
+8.8% vs TC avg
Strong +32% interview lift
Without
With
+31.6%
Interview Lift
resolved cases with interview
Typical timeline
2y 6m
Avg Prosecution
35 currently pending
Career history
846
Total Applications
across all art units

Statute-Specific Performance

§101
2.3%
-37.7% vs TC avg
§103
22.3%
-17.7% vs TC avg
§102
24.5%
-15.5% vs TC avg
§112
36.2%
-3.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 811 resolved cases

Office Action

§103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 23-42 are currently pending. Claims 23, 40 and 42 are independent. Priority The instant application claims priority as follows: PNG media_image1.png 32 358 media_image1.png Greyscale and of PNG media_image2.png 20 258 media_image2.png Greyscale . Election/Restriction Applicants’ election with traverse of Group I, claims 23-39, PNG media_image3.png 80 586 media_image3.png Greyscale , in the reply filed January 8, 2026 is acknowledged. The traversal is on the grounds that if the search and examination of an entire application can be made without serious burden, the Examiner must examine it on the merits, even though it arguably may include claims to distinct or independent inventions. Applicant additionally states that it would not place an undue burden on the Examiner to search the subject matter of the claims of Groups I to III as a search to one group would likely yield results applicable to the other group. Applicant’s arguments are found unpersuasive for the reasons of record and the following reasons. This application is a National Stage Application submitted under 35 USC 371, and as such unity of invention (not restriction practice pursuant to 37 CFR 1.141 - 1.146 ) is applicable. See MPEP 1893.03(d). The examiner previously stated that under PCT Rule 13.1 and 13.2 the claims herein lack unity of invention. Arguments that the search would not impose a serious burden on the Office, or that a search for one group may uncover results applicable to the other group, are not germane to the showing of Lack of Unity. The requirement is deemed proper and therefore made FINAL. Claims 40-42 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to nonelected inventions, there being no allowable generic or linking claim. Applicant timely traversed the restriction requirement in the reply filed on 01/08/2026. Claims 23-39 are the subject of this Office Action. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 23-30, 37 and 39 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The term “primary alkyl group” is unclear in the claims in view of the disclosure and claim 37. Alkyl carbons are classified as primary, secondary, tertiary and quaternary according to the number of carbons directly attached to the carbon in question. The carbon in question in this case is the carbon substituent attached to the phenyl ring represented by R2. Thus, when the substituent on the phenyl ring is a methyl group, the methyl carbon would be classified as a primary alkyl for being attached to only one carbon of the phenyl ring. However, if the substituent would be an ethyl group, the ethyl carbon directly attached to the phenyl group would be classified as a secondary alkyl carbon for being attached on one side to a carbon of the phenyl group and on the other side to an end methyl group. The scope of “primary alkyl groups” here should not include ethyl, propyl, butyl, pentyl, etc., since these would all be secondary. Only the methyl group would be a primary alkyl group, and in accordance with this, the recitation of claim 37 of PNG media_image4.png 26 206 media_image4.png Greyscale does not make sense. If the case was that applicant assigns the classification as a primary alkyl to the alkyl in question without counting the attachment to the carbon of the phenyl group, the examiner would say that in that case a methyl group would not be encompassed by the “primary alkyl group” term, because without counting the phenyl group attachment a methyl group is not attached to another carbon. PNG media_image5.png 364 620 media_image5.png Greyscale This rejection can be overcome by defining in the claims the specific alkyl groups that can substitute R2. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 23-30, 34, 36-39 are rejected under 35 U.S.C. 103 as being unpatentable over Foo (US 5,821,378) and Tam et al. (US 5,723,641), in view of Paciello (Angew. Chem. Int. Ed. 1999, 38, No. 13/14; p. 1920-1923) and Steyer (Dalton Trans., 2005, 1301-1309), and references therein. Teachings of Foo Foo disclosed an improved process for the hydrocyanation of diolefinic compounds (and subsequent isomerization of the resulting 2-alkyl-3-monoalkenenitriles to 3 and/or 4-monoalkene linear nitriles) comprising reacting an acyclic aliphatic diolefinic compound with a source of HCN in the presence of a catalyst precursor comprising zero-valent nickel and at least one multidentate phosphite ligand selected from Formulas I -XV, wherein ligands of formula II are calix[4]arene bisphosphites of the following formula: PNG media_image6.png 326 340 media_image6.png Greyscale PNG media_image7.png 125 340 media_image7.png Greyscale and wherein the diolefinic compounds of the claims are selected from 1,3-butadiene, 1,3-pentadiene and others. See at least claims 1, 15, 6, 16 and 20. Foo also taught that: PNG media_image8.png 62 360 media_image8.png Greyscale PNG media_image9.png 90 262 media_image9.png Greyscale PNG media_image10.png 130 287 media_image10.png Greyscale . See at least column 15. Foo recognized that some multidentate phosphite ligands useful in the present invention for the hydrocyanation of diolefins have been used for the hydrocyanation of monoolefins. Teachings of Tam Tam et al. taught the hydrocyanation reaction of monoolefins with HCN catalyzed by calix[4]arene diphosphite ligands of the following formula II: PNG media_image11.png 564 360 media_image11.png Greyscale in a complex with zero-valence nickel. The process provides hydrocyanation of the following monoolefins (col. 8): PNG media_image12.png 266 366 media_image12.png Greyscale See Examples 58-61. Example 61 used ligand G in the reaction: PNG media_image13.png 198 306 media_image13.png Greyscale PNG media_image14.png 206 354 media_image14.png Greyscale Tam disclosed that some of the ligands used therein for the hydrocyanation reaction of olefins have been disclosed to be useful for the hydroformylation reaction of olefins in catalyst complexes with rhodium (column 1, lines 63-67). Teachings of Paciello Paciello teaches the same ligand described in Tam for the hydroformylation of olefins, and structural variants 2, 3 and 4. Paciello taught that the calix[4]arene bisphosphites with bis-ortho methyl (3) or bis-ortho-isopropyl (2), produce a significant improvement in activity in a hydroformylation reaction with half the reaction time as compared to the tert-butyl substituted calix[4]arene bisphosphate (1) described in Tam. PNG media_image15.png 226 356 media_image15.png Greyscale PNG media_image16.png 238 354 media_image16.png Greyscale Paciello also recognized that their catalysts produce olefin isomerization. See the third paragraph at page 1922 and the section named “Hydroformylation experiments”. Teachings of Steyer Steyer taught additional calix[4]arene bisphosphite ligands of formula PNG media_image17.png 162 160 media_image17.png Greyscale useful in providing high selectivity for lineal aldehydes when used in complexes as catalysts for hydroformylation of olefins. Ascertainment of the difference between the prior art and the claims (MPEP §2141.02) The difference between the process of Foo or Tam and the claimed process is only the particular calix[4]arene bisphosphite ligands used in the reaction. Finding of prima facie obviousness--rational and motivation (MPEP §2142-2413) The level of skill is the level of the authors of the references cited in this action. Chelating aryl bisphosphite complexes were known to be excellent catalysts for both hydrocyanation and hydroformylation of olefins. See at least the references cited in Tam et al. and Foo, particularly the Baker references, and US 6,660,876. See also the calix[4]arene bisphosphite ligand in Paciello that was used in both hydrocyanation and hydroformylation reactions. Calix[4]arene bisphosphite ligands in catalyst complexes comprising zero-valence nickel were known in the art to catalyze the hydrocyanation reaction of olefins, per Foo and Tam et al. Additional calix[4]arene bisphosphite ligands were known in the art to be used in the related hydroformylation reaction. The Supreme Court in KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398, 415-421, 82 USPQ2d 1385, 1395-97 (2007) identified a number of rationales to support a conclusion of obviousness which are consistent with the proper "functional approach" to the determination of obviousness as laid down in Graham. See MPEP 2143. Examples of rationales that may support a conclusion of obviousness include: (A) Combining prior art elements according to known methods to yield predictable results; (B) Simple substitution of one known element for another to obtain predictable results; (C) Use of known technique to improve similar devices (methods, or products) in the same way; (D) Applying a known technique to a known device (method, or product) ready for improvement to yield predictable results; (E) "Obvious to try" – choosing from a finite number of identified, predictable solutions, with a reasonable expectation of success; (F) Known work in one field of endeavor may prompt variations of it for use in either the same field or a different one based on design incentives or other market forces if the variations are predictable to one of ordinary skill in the art; (G) Some teaching, suggestion, or motivation in the prior art that would have led one of ordinary skill to modify the prior art reference or to combine prior art reference teachings to arrive at the claimed invention. Applying KSR example rationales (B) and (G), it would have been prima facie obvious to substitute the ligand catalyst in the hydrocyanation reactions of Foo or Tam with for example, the ligand catalyst of Paciello of formula 3 PNG media_image18.png 274 258 media_image18.png Greyscale , and the ligand catalysts of Steyer of formula PNG media_image17.png 162 160 media_image17.png Greyscale . These ligands have the same calix[4]arene aryl bisphosphite core, and are known to be useful in the same type of reactions. A skilled artisan would have been motivated to make such a substitution in order to search for improvements on the hydrocyanation reaction of the references, just like Paciello and Steyer tested various calix[4]arene aryl bisphosphite ligands searching for improvement on the hydroformylation reaction. A skilled artisan would have reasonably expected that such a substitution would work because calix[4]arene aryl bisphosphite ligands are used in the hydrocyanation of olefins. With respect to the specific embodiment recited in claims 28 and 38, Paciello showed better reactivity when ligand of formula 3 PNG media_image18.png 274 258 media_image18.png Greyscale was used in the hydroformylation reaction compared to the ligand of Tam et al. It would have been prima facie obvious to make and use the position isomer of claim 28 and 38 of the formula PNG media_image19.png 270 246 media_image19.png Greyscale in which a methyl group is at position 4 instead of position 6 (as Paciello) because of the expectation of similar properties. The hydrocyanation of olefins using this ligand would have been obvious. The isomer is expected to be preparable by the same method and to have generally the same properties. Position isomers are a basic form of close “structural isomers.” MPEP 2144.09, second paragraph, states, “Compounds which are position isomers or homologs are generally of sufficiently close structural similarity that there is a presumed expectation that such compounds possess similar properties.” In re Wilder, 563 F.2d 457, 195 USPQ 426 (CCPA 1977). Note to Applicants Not every piece of prior art found in the search has been applied against the instant claims. See MPEP 904.03. Conclusion Claims 31-33 and 35 are objected to for depending of rejected claims. Claims 23-30, 34, 36-39 are rejected. Any inquiry concerning this communication or earlier communications from the examiner should be directed to VALERIE RODRIGUEZ-GARCIA whose telephone number is (571)270-5865. The examiner can normally be reached Monday-Friday 9:30am-5:30pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Clinton Brooks can be reached at 571-270-7682. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /VALERIE RODRIGUEZ-GARCIA/Primary Examiner, Art Unit 1621
Read full office action

Prosecution Timeline

Jan 16, 2025
Application Filed
Feb 04, 2026
Non-Final Rejection — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12593845
2,6-DIOXO-3,6-DIHYDROPYRIMIDINE COMPOUND, AGRICULTURAL AND HORTICULTURAL BACTERICIDE, NEMATICIDE, AND MEDICAL AND VETERINARY ANTIFUNGAL AGENT
2y 5m to grant Granted Apr 07, 2026
Patent 12577243
Monoacylglycerol Lipase Modulators
2y 5m to grant Granted Mar 17, 2026
Patent 12568969
PYRIDINE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS
2y 5m to grant Granted Mar 10, 2026
Patent 12570618
NOVEL COMPOUND, PRODUCTION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION
2y 5m to grant Granted Mar 10, 2026
Patent 12559466
IMPROVED PROCESS FOR PREPARATION OF INTERMEDIATES
2y 5m to grant Granted Feb 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
69%
Grant Probability
99%
With Interview (+31.6%)
2y 6m
Median Time to Grant
Low
PTA Risk
Based on 811 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month